Good morning and welcome to Markets Desk, your midday read on what's moving markets and why.
Microsoft is giving investors plenty to work with after its cloud business delivered a strong performance, adding weight to a valuation story that now stretches toward six hundred seventy eight billion dollars in justification. Azure's continued momentum reinforces the thesis that enterprise AI spending is translating into real revenue, not just headlines.
Shifting to pharma, AstraZeneca's reported interest in Bristol Myers Squibb is generating serious strategic debate on both sides of the Atlantic. The deal logic pulls in several directions at once — oncology scale, cardiovascular diversification, patent cliff protection, and a deeper footprint in the American market. Analysts are still untangling which motive is doing the heaviest lifting.
And in the energy transition, new data suggests China's coal consumption may finally be plateauing in a meaningful way. Renewable buildout is absorbing more of the country's power demand growth, and cleantech investors are watching closely, with some analysts beginning to talk about conditions ripe for a so-called super cycle in clean energy capital allocation. The signal is early, but it is not nothing.
That's the tape. Markets Desk, signing off the floor.
